Development Of Immune Tolerance Therapies For The Treatment Of Rheumatic Diseases

Last update: May 8, 2020 Last update: May 8, 2020

Details

Location:

EU 27

Funding agency:

Horizon 2020 (2014 - 2020)

Contracting authority type:Development Institution

Status:Awarded

Budget:N/A

Award ceiling:N/A

Award floor:N/A

Sector:Health, Research

Eligible applicants:Unrestricted / Unspecified

Eligible citizenships:

EU 27

Date posted: Apr 27, 2016

Attachments • 1

Associated Awards

Description

Call updates

27 April 2016 18:30 The submission session is now available for: IMI2-2016-09-02(IMI2-RIA)

TOPIC : DEVELOPMENT OF IMMUNE TOLERANCE THERAPIES FOR THE TREATMENT OF RHEUMATIC DISEASES

Topic identifier:	IMI2-2016-09-02
Publication date:	27 April 2016

Types of action:	IMI2-RIA Research and Innovation action
DeadlineModel: Planned opening date:	two-stage 27 April 2016	Deadline: 2nd stage Deadline:	26 July 2016 17:00:00 10 January 2017 17:00:00

Time Zone : (Brussels time)

Horizon 2020

Call identifier: H2020-JTI-IMI2-2016-09-TWO-STAGE

Topic Description

Specific Challenge:

Autoimmune diseases affect approximately 5% of the population of Europe, with two-thirds of the patients being female.

Scope:

Development of a translational research project for the induction and monitoring of immune tolerance in Rheumatic Diseases: Rheumatoid Arthritis (RA).

Expected Impact:

If successful, immune tolerance approaches would revolutionize treatment of RA by inducing drug-free remission. Coupled with diagnostic tests, screening initiatives for “at-risk” individuals, it may stop the disease before joint damage can occur. For healthy but at-risk patient, this would offer a screening and “vaccination” for the prevention of RA.

Want to unlock full information?

Member-only information. Become a member to access this information. Procurement notices from over 112+ donors and banks are available here

Learn more about our membership benefits